Tradestie Institutional Equity Comparison Engine

EQ vs NVCT โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NVCT Overall Edge

NVCT Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nuvectis Pharma, Inc. Common Stock (NVCT) driven by superior Momentum & Technical, Options & Structure while EQ counters with relative strength in Valuation. Fundamentally, EQ trades at 1.5x Forward P/E with 0.0% operating margin (-52.3% YoY revenue) versus NVCT at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EQ sits in UNCLASSIFIED (100th %ile IV; Dealer Gamma Walls on Pro) against NVCT sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner EQ
EQ 1.5x vs NVCT N/M Fwd P/E
Growth & Margin Winner Tie
Op Margin 0.0% vs 0.0% ยท YoY -52.3% vs +0.0%
Momentum & Technical Winner NVCT
1Y +12.0% vs +227.9% ยท 52W Pos 11% vs 60%
Options & Structure Winner NVCT
UNCLASSIFIED (100th %ile IV) vs BREAKDOWN (17th %ile IV)
EQ NASDAQ
Equillium, Inc. Common Stock
Pharmaceutical Preparations
$1.12
+1.82% 1D
Market Cap $90.6M
1M Return -21.13%
1Y Return +12.0%
Forward P/E 1.5x
Unified AI Score
48.0 / 100 HOLD
Tech 30.0 Fund 51.0 Flow 63.0 Mom 60.0
NVCT NASDAQ
Nuvectis Pharma, Inc. Common Stock
Pharmaceutical Preparations
$19.84
-2.22% 1D
Market Cap $697.8M
1M Return -4.15%
1Y Return +227.93%
Forward P/E N/M
Unified AI Score
45.4 / 100 HOLD
Tech 30.0 Fund 54.0 Flow 68.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: EQ +12.0% NVCT +227.93% Spread: +215.93 pp (NVCT Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
EQ TTM Op. Margin: 0.0% NVCT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EQ vs NVCT. Trailing 12-month operating profitability (EQ 0.0% vs NVCT 0.0%) and valuation multiples (EQ 1.5x vs NVCT N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: EQ (4) vs NVCT (4)
Institutional Metric EQ NVCT Criterion Row Winner
Market Capitalization Scale $90.6M $697.8M Larger Scale NVCT
Trailing P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Forward P/E Ratio Valuation 1.5x N/M Lower Multiple EQ
Revenue Growth (YoY) Growth -52.3% +0.0% Higher Growth NVCT
Operating Margin (TTM) Profitability 0.0% 0.0% Higher Margin Tie
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -59.0% -67.0% Higher ROE EQ
52-Week Range Position Momentum 11% ($1โ€“$4) 60% ($6โ€“$29) Stronger Trend NVCT
Beta / 30D Volatility Risk Regime 1.53ฮฒ ยท 93% Vol 0.67ฮฒ ยท 79% Vol Lower Realized Risk NVCT
Unified Institutional Score Composite Signal 48.0 / 100 (HOLD) 45.4 / 100 (HOLD) Higher Composite EQ

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full EQ vs NVCT Buy Guide
EQ UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live EQ Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
NVCT BREAKDOWN
101d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 17th %ile
IV Regime Compressed (<25th %ile)
Live NVCT Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither EQ nor NVCT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.